Invex Therapeutics Ltd. AI Stock Analysis
Want to see AU:IXC full AI Analyst Report?
Invex Therapeutics Ltd. (IXC) AI Stock Analysis
Invex Therapeutics Ltd.
(ASX:IXC)
The overall score of 41 reflects a high-risk, distressed biotechnology company. The most significant factor is the dire financial performance, characterized by zero revenue, persistent cash burn, and a rapidly shrinking equity base, which heavily weights the score downward. Valuation is equally poor due to negative earnings. The only modestly positive signal comes from the technical analysis, where the stock price trades above its major moving averages, but this is insufficient to offset the severe fundamental weaknesses.
Invex Therapeutics Ltd. (IXC) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 7.60M
- Dividend Yield
- ―
- Average Volume (3M)
- 79.68K
- Price to Earnings (P/E)
- -4.7
- Beta (1Y)
- 0.17
- Revenue Growth
- ―
- EPS Growth
- -185.71%
- Country
- Australia
- Employees
- 4
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Invex Therapeutics Ltd. Business Overview & Revenue Model
Company Description
Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurological...
Invex Therapeutics Ltd. Financial Statement Overview
Summary
Financial performance is critically weak. The company is pre-revenue with a complete halt in income, persistent net losses, and a rapidly eroding equity base down 88% from its peak. Cash flow is consistently negative with no capital investment for growth. The only mitigating factor is a debt-free balance sheet, preventing immediate insolvency, but the overall trajectory points toward a terminal wind-down phase.
Income Statement
8Very NegativeBalance Sheet
55NeutralCash Flow
15Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 229.08K | 1.21M | 459.08K | 182.25K |
| Gross Profit | 0 | 0 | 229.08K | 1.21M | 459.08K | 182.25K |
| EBITDA | -1.54M | -1.54M | 0 | -720.37K | 337.94K | -4.14M |
| Net Income | -1.35M | -1.35M | -476.87K | -1.64M | -7.75M | -3.95M |
Balance Sheet | ||||||
| Total Assets | 4.06M | 4.06M | 5.47M | 6.12M | 22.80M | 29.49M |
| Cash, Cash Equivalents and Short-Term Investments | 4.02M | 4.02M | 5.38M | 6.03M | 22.47M | 29.34M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 153.47K | 153.47K | 220.59K | 431.63K | 1.57M | 1.00M |
| Stockholders Equity | 3.91M | 3.91M | 5.25M | 5.69M | 21.23M | 28.48M |
Cash Flow | ||||||
| Free Cash Flow | -1.36M | -1.36M | -652.57K | -2.44M | -6.87M | -3.38M |
| Operating Cash Flow | -1.36M | -1.36M | -652.57K | -2.44M | -6.87M | -3.38M |
| Investing Cash Flow | -2.50M | -2.50M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 0 | 0 | 0 | -14.00M | 0 | 0 |
Invex Therapeutics Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IXC, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.10, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 29.85 is Positive, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IXC.
Invex Therapeutics Ltd. Peers Comparison
Overall Rating
AU:TRP47Neutral
AU:ACR44Neutral
AU:IXC41Neutral
AU:AGN39Underperform
AU:CMB39Underperform
AU:BOT38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | AUD 5.86M | -1.24 | -52.04% | ― | 32.22% | -26.53% | |
| 44Neutral | AUD 5.82M | -6.43 | -45.29% | ― | 290.25% | 92.05% | |
| 41Neutral | AUD 7.34M | -4.72 | -31.98% | ― | ― | -185.71% | |
| 39Underperform | AUD 14.13M | -10.38 | -29.22% | ― | ― | 81.00% | |
| 39Underperform | AUD 10.30M | -1.39 | -247.44% | ― | -4.24% | 33.39% | |
| 38Underperform | AUD 27.63M | -0.31 | -118.74% | ― | 499.47% | 31.20% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:IXC | Invex Therapeutics Ltd. | 0.09 | -0.03 | -29.17% | |
| AU:ACR | Acrux Limited | 0.01 | -0.00 | -33.33% | |
| AU:TRP | Tissue Repair Ltd | 0.11 | -0.19 | -63.33% | |
| AU:CMB | Regeneus Ltd. | 0.35 | -0.16 | -31.37% | |
| AU:AGN | Argenica Therapeutics Ltd | 0.11 | -0.10 | -47.62% | |
| AU:BOT | Botanix Pharmaceuticals Limited | 0.01 | -0.11 | -91.67% |
Invex Therapeutics Ltd. Corporate Events
Invex Sets Shareholder Meeting as Transactions Deemed Not Fair
Invex Therapeutics Ltd will hold a general meeting of shareholders in Perth on 4 December 2026, with meeting materials available online through its website and the ASX platform. Shareholders may vote by proxy electronically, while printed notices and...
Invex Therapeutics Raises A$900,000 via Share Placement and Confirms Regulatory Compliance
Invex Therapeutics Ltd., an Australian biopharmaceutical firm, is developing Presendin, a repurposed form of exenatide intended to treat neurological conditions associated with elevated intracranial pressure, such as acute stroke and traumatic brain...
Invex Therapeutics Seeks ASX Quotation for 11.25 Million New Shares
Invex Therapeutics Ltd. is a biotechnology company listed on the ASX under the ticker IXC, focused on developing therapeutic products. The company operates in the life sciences sector, targeting medical conditions where novel treatments can unlock ne...
Invex Therapeutics to acquire Rekover and raise $10m for neurology pipeline
Invex Therapeutics has agreed to acquire New Zealand-based Rekover Therapeutics, gaining a Phase 2a clinical program repurposing nalfurafine for demyelinating diseases, including chronic optic neuropathy in multiple sclerosis. The all-scrip deal is t...
Invex Therapeutics Plans Major Equity Issue and New Performance Rights
Invex Therapeutics Ltd has notified the ASX of a proposed securities issue that includes 45 million new ordinary fully paid shares and a total of 91.25 million performance rights across three new classes, A, B and C. The proposed issue, structured as...
Invex Therapeutics Plans Major ASX Securities Issue
Invex Therapeutics has announced a proposed issue of new securities on the ASX, comprising up to 113,750,000 fully paid ordinary shares and 19,500,000 options exercisable at $0.14 and expiring on 14 December 2029. The placement or other form of issue...
Invex Therapeutics Halts ASX Trading Ahead of Acquisition and Capital Raising
Invex Therapeutics has requested a trading halt in its shares on the ASX, effective immediately, as it prepares to release a material announcement to the market. The halt will remain in place until either the company publishes details of a planned ma...
Invex Therapeutics Sets Date and Online Access for 2026 AGM
Invex Therapeutics has called its 2026 Annual General Meeting of shareholders for 20 November 2026 at 10:00am in Perth, Western Australia. The meeting notice, explanatory memorandum, annual report and proxy materials are available online via the comp...
Invex Therapeutics Sets AGM Date and Director Nomination Deadline
Invex Therapeutics has scheduled its Annual General Meeting for 20 November 2026, with formal meeting documentation to be provided to shareholders in October. The company has set 2 October 2026 as the deadline for director nomination submissions, sig...
Invex Therapeutics Posts Deeper Loss but Strengthens Asset Backing in 2026
Invex Therapeutics Ltd reported a significantly wider loss for the year ended 30 June 2026, with loss after tax attributable to members rising to $1.35 million as other income fell sharply compared with the previous year. Despite the deeper losses, t...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026
